Mj. Heslin et al., PROGNOSTIC FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL FOR RETROPERITONEAL SARCOMA - IMPLICATIONS FOR MANAGEMENT, Journal of clinical oncology, 15(8), 1997, pp. 2832-2839
Purpose: Retroperitoneal soft tissue sarcomas are rare tumors. Studies
characterizing long-term follow-up and patterns of recurrence are lim
ited. The purpose of this analysis is to identify patterns of recurren
ce and prognostic factors associated with long-term survival after res
ection of retroperitoneal soft tissue sarcomas. Methods: Between July
1, 1982, and June 30, 1990, 198 adult patients were identified from ou
r prospective soft tissue sarcoma database carrying the diagnosis of r
etroperitoneal soft tissue sarcoma who were eligible for greater than
or equal to 5 years of follow-up. Of these, 48 patients (25%) were doc
umented to be alive greater than or equal to 5 years from the time of
operation. Statistical analysis was by log-rank or Wilcoxon test for u
nivariate analysis. Multivariate analysis was by the Cox model. Result
s: The recurrence rate during the follow-up period was approximately 5
% per year from the time of initial operation. Of the patients who wer
e disease-free for greater than or equal to 5 years from initial surge
ry, 40% recurred by 10 years. Radiation therapy was the only factor si
gnificant (P =.02) for a reduction in the risk of local recurrence. Ag
e less than or equal to 50 years and high-grade tumors were significan
t factors (P =.003 and .009, respectively) for an increased risk of di
stant metastasis. incomplete gross resection was the only factor signi
ficant for an increased risk of tumor mortality (P =.003).Conclusion:
Complete surgical resection at the time of primary presentation is lik
ely to afford the best chance for long-term survival. With long-term f
ollow-up, it is clear that recurrence will continue to occur, and a 5-
year disease-free interval is not a cure. Patients with an incomplete
initial resection, age less than 50 years, and high-grade tumors are c
andidates for investigational adjuvant therapy. (C) 1997 by American S
ociety of Clinical Oncology.